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ABSTRACT 
A simple, accurate, precise and stability indicating Ultra performance liquid chromatographic method for determination of pravastatin sodium in 
tablet dosage form. The separation was carried on Acquity UPLC ® HSS C18, 2.1 × 100mm, 1.8µm ID column, with mobile phase comprising of 
mixture of pH 5.5 buffer: methanol in the ratio of 30 : 70 v/v, as the mobile phase at a flow rate  0.2 ml/min and the detection was carried out 
using UV-visible detector at 238nm. The method was validated by evaluation of different parameters such as accuracy, precision, linearity, 
ruggedness, robustness, filter equivalency, solution stability. The retention time were found to be 1.5 min. Calibration curves were linear with 
correlation coefficient (r2) 0.999. The Percent assay of Pravastatin sodium tablet was found to be 98.4%. The developed methods were validated 
as per the ICH guidelines.  
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INTRODUCTION 
Chromatography is a non-destructive procedure for 
resolving a multi-component mixture of trace, minor, or 
major constituents into its individual fractions. UPLC refers 
to Ultra Performance Liquid Chromatography.1-5 It improves 
in three areas: chromatographic resolution, speed and 
sensitivity analysis. It uses fine particles and saves time and 
reduces solvent consumption. UPLC comes from HPLC. HPLC 
has been the evolution of the packing materials used to effect 
the separation. An underlying principle of HPLC dictates that 
as column packing particle size decreases, efficiency and 
thus resolution also increases. As particle size decreases to 
less than 2.5µm, there is a significant gain in efficiency and 
it’s doesn’t diminish at increased linear velocities or flow 
rates according to the common Van Demeter equation. By 
using smaller particles, speed and peak capacity (number of 
peaks resolved per unit time) can be extended to new limits 
which is known as Ultra Performance.6 
Drug Profile: 
Name: Pravastatin Sodium  
 
Structure of Pravastatin sodium 
Chemical Name : sodium  (3R,5R)-3,5-dihydroxy-7-
((1R,2S,6S,8R,8aR)-6hydroxy 2-methyl-8- {[(2S)-2-
methylbutanoyl]oxy}-1,2,6,7,8,8a-hexahydronaphthalen-1-
yl)-heptanoic acid 
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Molecular Formula: C23H35O7Na 
Molecular Weight : 446.5 
Category: Anti-hyperlipidemic 
Description: Pravastatin is white to yellowish white power 
or crystalline Powder, hygroscopic. 
BCS Class: High solubility, low permeability.                                                                                                                                                                                                                                                                                                                                                                
Solubility: Freely soluble in water and in methanol, soluble 
in ethanol. 
Melting point: 172-173 °C 
pH: 7.2 - 9.0  
Mode of Action: Pravastatin sodium is one of a new class of 
lipid- lowering compounds. The HMG-CoA reductase 
inhibitors, which reduce cholesterol biosynthesis. These 
agents are competitive inhibitors of 3-hydroxy-3-
methylglutaryl-co-enzyme A (HMG-CoA) reductase, the 
enzyme catalyzing the early rate-limiting step in cholesterol 
biosynthesis, conversion of HMG-CoA to mevalonate.7-11 
MATERIALS AND METHODS 
Instruments: 
1) Acquity Waters,Acquity PDA ,Empower 3 Software Build 
3471 
2) Balance RADWAG Wagl Elektroniczne, model-XA 
82|220|2X 
3) PH-meter used of LABINDIA  
4) Sonicator chiller  
5) Calibrated glasswares were used for the whole 
experimental work 
Reagents and Chemicals: 
All chemicals and solvents used for the experimental are 
from MERCK, RANKEM etc. enlisted as follows;  
1) HPLC/AR Grade Methanol 
2) HPLC Grade Water (Milli-Q) 
3) AR Grade Triethylamine 
4) Pravastatin Sodium, Glenmark Phramaceuticals 
Ltd.Taloja (Mumbai) 
Spectral study of Pravastatin Sodium: 
A solution of Pravastatin Sodium was prepared in methanol 
having concentration of 10 ppm. The above solution was 
taken in a 1 cm cell in order to obtain the Ultra violet (UV) 
spectrum of drug in the range 200-400 nm using UV 
spectrophotometer was recorded. The absorbance maxima 
or lambda max (λmax) of the drug was found to be 238 nm. 
Preparation of Diluent: Methanol: water (HPLC grade) 
50:50v/v  was used as diluent 
Preparation of Mobile Phase A:  
Added 5.0 ml glacial acetic acid in 1.5 liter of water. Adjusted 
the pH to 5.5 ± 0.05 with Triethylamine. Filtered through 
0.45µ nylon membrane filter. 
Preparation of Mobile Phase B: Methanol. 
Preparation of Standard Solution: 
Accurately weighed and transfered about 25 mg of 
Pravastatin Sodium working standard into a 50 ml 
volumetric flask. Added 30 mL of diluents and sonicated to 
dissolve. Made up the volume upto the marked and mixed. 
Diluted 5 ml of the above solution to 50 ml with diluents 
(50ppm) 
Preparation of Sample Solution: 
 Taken 5 intact tablets to 100 mL volumetric flask and 60 mL 
of diluent added then sonicated it for complete dispersion 
with intermittent swirling. Further sonicated for 15 minutes 
and diluted to volume with diluent. Allowed it to stand for 10 
minutes, diluted 5 mL of supernatant solution to 50 mL with 
diluent. Further Filtered through 0.45 µ nylon membrane 
filter. As shown in table no.2 
Optimized chromatographic method for Assay: 
Table1:  Data for Assay of Pravastatin Sodium tablet 
Parameter Condition 
UPLC System Wasters UPLC 
Stationary Phase Acquity UPLC  ® HSS C18 (2.1 × 
100mm, 1.8µ) 
Mobile Phase Buffer(pH 5.5) : Methanol(30:70) 
Flow Rate 0.2ml/min 
Detection 238nm 
Pump Mode Gradient 
Injection  Volume 2 µl 
Run Time 3 min 
Column Temperature 400C 
Retention Time 1 to 2 min 
 
Evaluation of System suitability: 
Inject the standard solution five times. The relative standard 
deviation of five replicate injections should not be more than 
2.0%. The Tailing factor for the Pravastatin Sodium peak 
should not be more than 2.0 and the number of theoretical 
plates should not be less than 2500. 
Method validation 
Method validation is the process to confirm that the 
analytical procedure employed for a specific test is suitable 
for its intended use. Method validation provides the method 
development extremely specific, Linear, Precise, accurate & 
sensitive. 12-22 
Linearity 
Linearity is the ability of the method to elicit test results that 
are directly proportional to analyte concentration within a 
given range. Linearity is generally reported as the variance of 
the slope of the regression line. It is demonstrated directly 
on the drug substance by dilution of a standard stock 
solution of the drug product components, using the proposed 
procedure. For the establishment of linearity, minimum of 
five concentrations is recommended by ICH guideline. The 
value of correlation co-efficient should fall around 0.99. The 
regression equation and correlation coefficient was 
calculated and found to be within the required limits as 
shown in Tables no.4 and figure no.3 respectively. 
Accuracy 
The test for accuracy is intended to demonstrate the 
closeness of agreement between the value found and the 
value that is accepted either as a conventional true value or 
as an accepted reference value. Thus the accuracy of a 
method is the closeness of the measured value to the true 
value for the sample. The accuracy can also be demonstrated 
by recovery of the impurity spiked to a drug substance or 
into a placebo with drug substance. The percentage recovery 
with the certain acceptance criteria at each defined level is 
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reported. Accuracy should be assessed using a minimum of 
nine determinations at a minimum of three concentration 
levels covering the specified range. The recovery results 
were shown in table no.5. 
Precision: 
The precision of analytical procedure expresses the 
closeness of agreement between series of measurements 
obtained from multiple sampling of the same homogeneous 
sample.The precision of an analytical procedure is usually 
expressed as the variance,standard deviation.The precision 
results were shown in table no.6 . 
Ruggedness 
Ruggedness is the degree of reproducibility of the results 
obtained under a Varity of conditions, expressed as %RSD. 
These conditions include different laboratories, analyst, 
instruments, reagents, days etc.The ruggedness results was 
shown in table no.7. 
Robustness  
The robustness of an analytical procedure is a measure of its 
capacity to remain unaffected by small but deliberate 
variations in method parameters. The robustness of a 
method is evaluated by varying method parameters such as 
percent organic, pH, wavelength, temperature, etc., and 
determining the effect on the results of the method.  The 
results of robustness study were shown in Tables no 9, 10, 
11 respectively.  
RESULTS AND DISCUSSION 
Assay data: The percent Assay of pravastatin sodium tablet 
was found to be 98.4% 
 
Table 2:  Data for Assay of Pravastatin Sodium tablet 
Wt.of Std (mg) Area of Standard Area of Sample  Purity of Standard % Assay 
 
 
25 
1359265 
1361568 
1356933 
1365771 
1361791 
1368275 
1365143 
 
 
 
98% 
 
 
 
98.4% 
Mean 1361066 1366709 
SD 3287.854  
% RSD 0.24  
 
Specificity: The retention time of the Pravastatin Sodium 
peak in the chromatogram of the Sample preparation 
corresponds to that of the Pravastatin Sodium peak in the 
chromatogram of the Standard preparation. The Pravastatin 
Sodium peak is pure in Standard solution and Sample 
solution. Blank and Placebo should not show any peak at the 
retention time of Pravastatin sodium. 
 
Table 3:  Specificity table for Pravastatin Sodium tablet 
SR. No. Name Purity Angle Purity Threshold 
1 Standard solution 0.418 1.640 
2 Sample solution 40 mg 0.381 1.616 
 
 
Figure 1: Chromatogram of Specificity Standard Solution. 
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Figure 2:  Chromatogram of Specificity Sample Solution 
 
Linearity: A series of solutions of Pravastatin Sodium 
Standard was prepared over a range of 30% to 70% of the 
standard concentration of Pravastatin Sodium in Pravastatin 
Sodium tablets. Since the standard concentration is 50 
µg/ml. Linear calibration graph was obtained between 
absorbance versus concentration of pravastatin sodium 
drug. Correlation coefficient was 0.99993. Therefore, the 
UPLC method for the determination of Pravastatin Sodium in 
Pravastatin Sodium tablets was linear. 
 
                    Table 4: Linearity for Pravastatin Sodium tablets 
% Concentration Concentration 
(µg per ml) 
Response 
(Area) 
Statistical analysis 
30% 30.432 831281 Slope 27168.2 
40% 40.576 1107490 
50% 50.720 1389802 Intercept -6284.1 
60% 60.864 1659407 
70% 71.008 1933293 Correlation Coefficient 0.99997 
         
 
Figure 3: Linearity Graph of Pravastatin Sodium. 
Accuracy (Recovery) 
Placebo of Pravastatin Sodium tablets 40 mg was spiked with 
Pravastatin Sodium Drug Substance at three different levels: 
80%, 100% and 120% of the label claim in triplicate (in total 
nine determinations) and then proceeded with Sample 
solution as described under Methodology. Each of the 
Sample solution was injected in duplicate and the average 
area count was taken for calculation. Mean recovery is 
100.5% & RSD is 1.02 %. Therefore, the UPLC method for the 
determination of Pravastatin Sodium in Pravastatin Sodium 
tablets was accurate. 
 
 
Table 5: Accuracy for Pravastatin Sodium tablets 
Sample No. Amount  added (mg) Amount recovered (mg) % Recovery 
Acc. 80% -1 31.85 31.90 100.2 
Acc. 80% -2 31.56 31.86 101.0 
Acc. 80% -3 31.48 31.83 101.1 
Acc. 100% -1 39.45 40.06 101.5 
Acc. 100% -2 39.32 39.87 101.4 
Acc. 100% -3 40.62 40.19 98.9 
Acc. 120% -1 48.59 48.33 99.5 
Acc. 120% -2 48.66 48.28 99.2 
Acc. 120% -3 48.27 48.88 101.3 
Mean 
SD 
% RSD 
100.5 
1.024 
1.02 
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Precision 
System Precision: Five replicate injections of the Standard 
preparation were injected into the UPLC using the method as 
described under Methodology. 
Method Precision: Six sample solutions of Pravastatin 
Sodium tablets 40 mg were prepared and injected into the 
UPLC using the method as described under Methodology. 
Table 6: System Precision for Pravastatin & Method 
Precision of Pravastatin Sodium tablet 
System Precision for Pravastatin 
Injection Area 
1 1321824 
2 1321593 
3 1324619 
4 1316424 
5 1321550 
Mean 1321202 
SD 2965.048 
%RSD 0.224 
Method Precision of Pravastatin Sodium tablet 
Sample % Label claim 
1 99.4 
2 99.2 
3 99.2 
4 98.9 
5 99 
6 99 
Mean 99 
SD 0.183 
%RSD 0.18 
                            
Six sample preparations of the Pravastatin Sodium Tablets 
40 mg were made by a different analyst, using different 
column on a different day and injected in duplicate into a 
different UPLC using the method as described under 
Methodology, along with Standard preparation. 
Table 7: Ruggedness for Pravastatin Sodium tablet 
Sample Analyst -1 
% Label 
claim 
Analyst -2 
% Label 
claim 
1 100.3 99.9 
2 99.9 99.8 
3 100.3 97.3 
4 100.4 99.6 
5 100.3 99.8 
6 99.9 99.8 
Mean 100 99 
SD 0.223 1.017 
%RSD 0.22 1.02 
Overall 
Mean 
99.5 
Overall SD 0.62 
            
Stability of Analytical solution 
The sample and standard preparations were stored at room 
temperature and tested against freshly prepared standard 
preparations for 24 hours. 
 
Table 8: Stability of Analytical solution at Room Temperature 
Sr. No. Name % Content 
0 hours 
% Content 
24 hours 
% Correlation 
1 Standard Solution -- 99.0 99.0 
2 Sample solution  98.9 100.6 101.7 
 
Robustness 
Three Sample preparations of the Pravastatin Sodium tablets 
40 mg were prepared as described under Methodology. The 
samples along with standard were injected in duplicate 
under different chromatographic condition as shown below. 
Change in mobile phase composition (+ 2% absolute):
 
Table 9: Table for mobile phase composition (+ 2% absolute) 
 Control +2% absolute -2% absolute 
99.9 99.6 99.9 100.5 
99.8 99.8 98.5 98.8 
97.3 99.8 99.1 99.4 
Mean 99.3 99.4 
SD 0.883 0.918 
%RSD 0.89 0.92 
 
Change in Flow rate (+ 0.1%): 
Table 10: Table for Change in Flow rate (+ 0.2 mL/min). 
Control +0.2ml/min -0.2ml/min 
99.9 99.6 98.8 100.0 
99.8 99.8 97.5 98.8 
97.3 99.8 98.0 99.3 
Mean 98.9 99.4 
SD 1.075 0.859 
%RSD 1.09 0.86 
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Change in wavelength (+ 5nm) 
Table 11: Table for Change in wavelength (λmax 238) 
Control + 5 (243nm) -5 (233nm) 
99.9 99.6 100.2 100.2 
99.8 99.8 99.5 99.5 
97.3 99.8 100.1 100.1 
Mean 99.6 99.6 
SD 0.873 0.873 
%RSD 0.88 0.88 
 
CONCLUSION 
The developed UPLC method offers several advantages such 
as rapidity, usage of simple mobile phase and sample 
preparation steps. Further, improved sensitivity makes it 
specific and reliable for its intended use. Hence, this method 
can be applied for the analysis of pharmaceutical dosage 
forms. From the present study it can be concluded that the 
proposed method was Simple, Linear, Precise, and Accurate 
for Assay of Pravastatin sodium in its tablet dosage form. 
Hence this method can be introduced into routine use for the 
assay & dissolution study of Pravastatin in Pravastatin 
sodium tablets.  Results of validation parameters 
demonstrated that the analytical procedure is suitable for its 
intended purpose and meets the criteria defined in ICH 
Q2A/B. 
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